Dr. Andrew X. Zhu is an internationally recognized leader in hepatocellular carcinoma (HCC) and cholangiocarcinoma. Dr. Zhu has served as a principal investigator in many pivotal clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers.  As the lead global principal investigator, he managed the pivotal studies which led to the regulatory approval of Pembrolizumab and Ramucirumab in advanced HCC. As a co-principal investigator, he lead the phase III trial of first IDH-1 inhibitor Ivosidenib in cholangiocarcinoma with IDH-1 mutations. Dr. Zhu established the multidisciplinary liver cancer clinic and conference at Massachusetts General Hospital in 2009.

Dr. Thomas Brown has more than 30 years of extensive experience in the management of tumor centers and has a deep understanding on the development of tumor therapy modalities. Dr. Brown's previous positions include serving as the Executive Director of the US Swedish Cancer Institute, where he was in charge of the operations of five major hospital areas. At the MD Anderson Cancer Center, Dr. Brown served numerous roles, including as Professor of Gastrointestinal Medical Oncology, Head of the Division of Cancer Medicine, and Vice President of International Operations for external projects. Dr. Brown also served as Professor of Medicine and Chief Operating Officer at the University of Arizona, and as a Professor at the Cancer Center of Duke University. 

Dr. Lieping Chen is an endowed chair professor at Yale University and director of the Cancer Immunology Program. Dr. Chen established the foundation work for the role of PD-L1/PD-1 pathway in tumor immune escape and implemented the strategy for blocking PD-L1/PD-1 with monoclonal antibodies to perform strategic cancer therapy. This important discovery enabled the development of antibody drugs which were approved for the market in 2014 for broad-spectrum treatment of solid tumors. In 2014, Dr. Chen was awarded the William B. Coley Award, a top honor in cancer immunology circles. In 2016, Dr. Chen was the first Chinese-American scientist to win the AAI-Steinman Award from the prestigious American Association of Immunologists. 

With an experience spanning 30 years in the Thoracic Surgery department at First Affiliated Hospital of Guangzhou Medical University, Professor He Jianxing has led his team to finish over 28,000 cases of thoracoscopy and thoracoscopic-assisted minimally-invasive chest surgery. This includes 73 cases of lung transplants, with the longest survival period reaching 11 years, as well as patients as late as the age of 81. He is currently the only expert in China who has successfully carried out a clinical allogeneic tracheal transplant and clinical allogeneic lung transplant. 

Professor Lu Shun is the Director of the Oncology Department of Shanghai Chest Hospital and is a leading expert in the medical industry in Shanghai. He specializes in the treatment of various common and rare lung diseases, and is at the forefront of the latest developments in lung cancer treatments both in China and overseas, with remarkable achievements in early diagnosis, targeted treatments, and comprehensive treatments for lung cancer. 

Dr. Jiping Wang specializes in minimally-invasive surgery for malignant gastrointestinal tumors, and has more than ten years of experience in clinical trials for breast cancer and intestinal tumors. With a solid background in biostatistics, he focuses on finding and identifying tumor markers for screening, efficacy assessment and prognosis, and aspires to develop algorithms and scoring systems for guiding tumor clinical studies and practices. Dr. Wang has consecutively won the Excellence Award presented at the ASCO Annual Meeting, in addition to the AACR and ACS Scholar Awards.